Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.53 |
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.50 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 7/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7054013 | 0.89 | KDM4E (0.44) | KDM4EMAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7071371 | 0.86 | KDM4E (0.42) | KDM4EMAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7057599 | 0.84 | KDM4E (0.40) | KDM4EMAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL3470444 | 0.81 | KDM4E (0.58) | KDM4EMAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL3469723 | 0.81 | KMT2A (0.58) | KDM4EMAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7073342 | 0.81 | KDM4E (0.38) | KDM4EMAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL24029264 | 0.79 | MPO (0.55) | KDM4EMAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7053255 | 0.79 | MPO (0.55) | KDM4EMAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL22833819 | 0.79 | MPO (0.55) | KDM4EMAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL24029263 | 0.79 | MPO (0.55) | KDM4EMAPTKMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | THE WISTAR INSTITUTE (US) | 2016-03-10 | — | — | US | disclosed |
| US-9234230-B2 | Screening method and compounds for modulating telomerase activity | THE WISTAR INSTITUTE (US) | 2016-01-12 | — | — | US | disclosed |
| US-8518940-B2 | FP-pocket-binding effectors and methods for using the same to modulate telomerase activity | THE WISTAR INSTITUTE (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | THE WISTAR INSTITUTE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20100158798-A1 | FP-Pocket-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity | THE WISTAR INSTITUTE | 2010-06-24 | — | — | US | disclosed |
| US-20030176314-A1 | Compounds for the treatment of pain | H. LUNDBECK A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | disclosed |
| WO-2003026657-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | TERT, TERB1, TERF2 | KDM4E 2189/4885MAPT 2733/4885KMT2A 2921/4885 |
| US-20030176314-A1 | Compounds for the treatment of pain | NPFFR2, NPFFR1, OPRL1 | KDM4E 4560/4885MAPT 2186/4885KMT2A 2310/4885 |
| US-20100158798-A1 | FP-Pocket-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity | TERF2IP, TERF2, TERT | KDM4E 2087/4885MAPT 3047/4885KMT2A 2483/4885 |
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | TERT, TERB1, TERF2 | KDM4E 2189/4885MAPT 2733/4885KMT2A 2921/4885 |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | NPFFR1, NPFFR2, SSTR3 | KDM4E 3447/4885MAPT 4577/4885KMT2A 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.